- Fry et al., Nature Medicine, 24, 20-28, 2018. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
- Tang, et al., Annals of Oncology, 29, 84-91, 2018. Comprehensive analysis of the clinical immuno-oncology landscape.
- Tang, et al., Nature Reviews Drug Discovery, 17, 783–784, 2018. Trends in the global immuno-oncology landscape.
- Biberacher et al. Haematol. 97: 771, 2012. Bryostatin enhances efficacy of an antibody drug conjugate against CD22 in vitro.
- Wojciechowski et al. J Immunol 174: 7859, 2005. Bryostatin enhances expression of CD20 in cancer cell line.
- Varterasian et al. Clin Cancer Res 6: 825, 2000. Bryostatin induces CD22 expression in early clinical study.
- Fry et al. Nature Med 24:20, 2018. CD22 CAR-T rescues CD19 CAR-T relapses.
- Ramakrishna et al. Blood (ASH Abstr) 130: 3894, 2017. Bryostatin enhances CD22 CAR-T efficacy in mice.
- Ramakrishna et al. Clinical Cancer Research, May 20, 2019. Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.
- Ariza et al. J Biol Chem 286: 24, 2011. Bryostatin is a TLR4 ligand & enhances cytokine/chemokine production from dendritic cells.
- Do et al. Cancer Res 64: 6756, 2004. Bryostatin enhances maturation of & antigen presentation by dendritic cells.
- Wang et al., Retrovirology. 15, 21, 2018. Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir.
- Marsden et al., Virology. 520, 83-93, 2018. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
- Wender et al., Science, 358, 218-223, 2017. Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV.
